PRRT genomic signature in blood for prediction of (177)Lu-octreotate efficacy

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) utilizes somatostatin receptor (SSR) overexpression on neuroendocrine tumors (NET) to deliver targeted radiotherapy. Intensity of uptake at imaging is considered related to efficacy but has low sensitivity. A pretreatment strategy to determine...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Nucl Med Mol Imaging
Main Authors: Bodei, Lisa, Kidd, Mark S., Singh, Aviral, van der Zwan, Wouter A., Severi, Stefano, Drozdov, Ignat A., Cwikla, Jaroslaw, Baum, Richard P., Kwekkeboom, Dik J., Paganelli, Giovanni, Krenning, Eric P., Modlin, Irvin M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6716527/
https://ncbi.nlm.nih.gov/pubmed/29484451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-018-3967-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados